OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (266)	10/6/2005 12:20:20 PM
From: former_pgs	Read Replies (1) of 447

>How much Tarceva penetrated second line treatment, is real thing for future projection (as for this indication one will expect longer treatment duration).< Tarceva's relative scripts in 2nd line isn't bad percentage wise. Of course, this is still pretty small compared to the total $$$ spent on the care of 2nd line NSCLC. From the UBS presentation: 1st line NSCLC, 7%; 2nd line 25%, 3rd line 30% 1st line Pancreatic, 19%

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next